Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.


Clinical Trial Description

The trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and every 3 patient is a dose group. ;


Study Design

Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02131688
Study type Interventional
Source CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact
Status Recruiting
Phase Phase 1
Start date May 2013
Completion date October 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03346096 - TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma Phase 2
Completed NCT05190263 - Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Completed NCT01473095 - Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Phase 1
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Completed NCT00685997 - Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas N/A
Not yet recruiting NCT06358001 - EchoTip AcuCore Post-Market Clinical Study
Recruiting NCT04986293 - CPAP or BiPAP for Motion Mitigation During Radiotherapy N/A
Completed NCT01588548 - Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma Phase 1
Withdrawn NCT04464889 - HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation Phase 1
Completed NCT03316144 - Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma Phase 1
Terminated NCT01016795 - Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma Phase 2
Completed NCT04464590 - Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
Recruiting NCT04698616 - Lean Body Mass and Side Effects in Patients With Lymphoma
Active, not recruiting NCT02678299 - Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study Phase 1/Phase 2
Completed NCT01499147 - Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies N/A
Completed NCT01789060 - p-AKT Expression on Clinical Outcomes in Malignant Lymphoma N/A
Completed NCT05827341 - A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Active, not recruiting NCT05515029 - Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis Phase 3
Not yet recruiting NCT05545202 - A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Phase 4